Inozyme Pharma Stock Working Capital

INZY Stock

USD 2.81 0.12 4.46%

Inozyme Pharma fundamentals help investors to digest information that contributes to Inozyme Pharma's financial success or failures. It also enables traders to predict the movement of Inozyme Stock. The fundamental analysis module provides a way to measure Inozyme Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Inozyme Pharma stock.

	Last Reported	Projected for Next Year
Net Working Capital	181.6 M	115.1 M
Change In Working Capital	-3.1 M	-2.9 M

Net Working Capital is likely to drop to about 115.1 M in 2024. Change In Working Capital is likely to rise to about (2.9 M) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Inozyme Pharma Company Working Capital Analysis

Inozyme Pharma's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Current Inozyme Pharma Working Capital

181.56 M

Most of Inozyme Pharma's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inozyme Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Inozyme Working Capital Driver Correlations

Understanding the fundamental principles of building solid financial models for Inozyme Pharma is extremely important. It helps to project a fair market value of Inozyme Stock properly, considering its historical fundamentals such as Working Capital. Since Inozyme Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Inozyme Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Inozyme Pharma's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Capital Surpluse	Total Liab	Deferred Long Term Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Common Stock	Property Plant Equipment	Current Deferred Revenue	Long Term Investments	Short Term Debt	Long Term Debt	Long Term Debt Total
Total Assets		0.98	0.97	-0.05	-0.88	0.74	0.78	1.0	0.94	-0.63	0.87	0.99	1.0	1.0	0.82	0.82	0.78	-0.77	0.8	0.67	-0.51
Total Stockholder Equity	0.98		1.0	-0.16	-0.83	0.85	0.67	0.97	0.93	-0.79	0.82	0.99	0.96	0.96	0.73	0.88	0.76	-0.75	0.76	0.51	-0.41
Net Tangible Assets	0.97	1.0		-0.18	-0.81	0.86	0.63	0.97	0.91	-0.79	0.82	0.99	0.96	0.95	0.7	0.88	0.76	-0.74	0.75	0.48	-0.37
Net Debt	-0.05	-0.16	-0.18		-0.38	-0.42	0.32	-0.03	0.17	0.35	0.02	-0.08	0.0	-0.01	0.42	-0.03	0.46	-0.5	0.5	0.49	-0.49
Retained Earnings	-0.88	-0.83	-0.81	-0.38		-0.57	-0.89	-0.89	-0.97	0.49	-0.8	-0.86	-0.9	-0.89	-0.97	-0.73	-0.89	0.94	-0.95	-0.78	0.75
Accounts Payable	0.74	0.85	0.86	-0.42	-0.57		0.35	0.73	0.74	-0.95	0.64	0.78	0.7	0.69	0.44	0.82	0.5	-0.55	0.51	0.04	-0.18
Net Receivables	0.78	0.67	0.63	0.32	-0.89	0.35		0.78	0.84	-0.23	0.69	0.72	0.8	0.81	0.94	0.5	0.61	-0.7	0.72	0.9	-0.9
Short Term Investments	1.0	0.97	0.97	-0.03	-0.89	0.73	0.78		0.94	-0.63	0.89	0.99	1.0	1.0	0.81	0.84	0.8	-0.78	0.81	0.67	-0.51
Capital Surpluse	0.94	0.93	0.91	0.17	-0.97	0.74	0.84	0.94		-0.67	0.82	0.94	0.94	0.94	0.92	0.83	0.85	-0.9	0.9	0.67	-0.68
Total Liab	-0.63	-0.79	-0.79	0.35	0.49	-0.95	-0.23	-0.63	-0.67		-0.44	-0.71	-0.6	-0.59	-0.37	-0.81	-0.48	0.54	-0.49	0.03	0.14
Deferred Long Term Liab	0.87	0.82	0.82	0.02	-0.8	0.64	0.69	0.89	0.82	-0.44		0.84	0.87	0.87	0.68	0.78	0.76	-0.72	0.75	0.54	-0.38
Net Invested Capital	0.99	0.99	0.99	-0.08	-0.86	0.78	0.72	0.99	0.94	-0.71	0.84		0.99	0.99	0.78	0.86	0.79	-0.77	0.8	0.61	-0.46
Total Current Assets	1.0	0.96	0.96	0.0	-0.9	0.7	0.8	1.0	0.94	-0.6	0.87	0.99		1.0	0.84	0.81	0.8	-0.78	0.82	0.7	-0.53
Net Working Capital	1.0	0.96	0.95	-0.01	-0.89	0.69	0.81	1.0	0.94	-0.59	0.87	0.99	1.0		0.83	0.8	0.79	-0.77	0.8	0.71	-0.53
Common Stock	0.82	0.73	0.7	0.42	-0.97	0.44	0.94	0.81	0.92	-0.37	0.68	0.78	0.84	0.83		0.57	0.78	-0.86	0.87	0.85	-0.86
Property Plant Equipment	0.82	0.88	0.88	-0.03	-0.73	0.82	0.5	0.84	0.83	-0.81	0.78	0.86	0.81	0.8	0.57		0.78	-0.79	0.76	0.35	-0.33
Current Deferred Revenue	0.78	0.76	0.76	0.46	-0.89	0.5	0.61	0.8	0.85	-0.48	0.76	0.79	0.8	0.79	0.78	0.78		-0.96	0.98	0.61	-0.44
Long Term Investments	-0.77	-0.75	-0.74	-0.5	0.94	-0.55	-0.7	-0.78	-0.9	0.54	-0.72	-0.77	-0.78	-0.77	-0.86	-0.79	-0.96		-0.99	-0.62	0.61
Short Term Debt	0.8	0.76	0.75	0.5	-0.95	0.51	0.72	0.81	0.9	-0.49	0.75	0.8	0.82	0.8	0.87	0.76	0.98	-0.99		0.68	-0.59
Long Term Debt	0.67	0.51	0.48	0.49	-0.78	0.04	0.9	0.67	0.67	0.03	0.54	0.61	0.7	0.71	0.85	0.35	0.61	-0.62	0.68		-0.8
Long Term Debt Total	-0.51	-0.41	-0.37	-0.49	0.75	-0.18	-0.9	-0.51	-0.68	0.14	-0.38	-0.46	-0.53	-0.53	-0.86	-0.33	-0.44	0.61	-0.59	-0.8

Click cells to compare fundamentals

Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.

Competition

Predict Inozyme Pharma

Working Capital Over Time

Inozyme Capital Surpluse

Capital Surpluse

402.53 Million

At this time, Inozyme Pharma's Capital Surpluse is fairly stable compared to the past year.

According to the company's disclosures, Inozyme Pharma has a Working Capital of 181.56 M. This is 57.34% lower than that of the Biotechnology sector and 66.29% lower than that of the Health Care industry. The working capital for all United States stocks is 87.72% higher than that of the company.

Inozyme Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inozyme Pharma's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inozyme Pharma could also be used in its relative valuation, which is a method of valuing Inozyme Pharma by comparing valuation metrics of similar companies.

Inozyme Pharma is currently under evaluation in working capital category among its peers.

Inozyme Pharma Current Valuation Drivers

We derive many important indicators used in calculating different scores of Inozyme Pharma from analyzing Inozyme Pharma's financial statements. These drivers represent accounts that assess Inozyme Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Inozyme Pharma's important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	265.9M	482.7M	160.7M	39.7M	220.8M	263.1M
Enterprise Value	234.3M	324.1M	140.7M	13.5M	232.8M	215.4M

Inozyme Pharma ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Inozyme Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Inozyme Pharma's managers, analysts, and investors.

Environmental

Governance

Social

Inozyme Fundamentals

	Return On Equity	-0.79
	Return On Asset	-0.36
	Current Valuation	95.7 M
	Shares Outstanding	64.24 M
	Shares Owned By Insiders	0.50 %
	Shares Owned By Institutions	96.67 %
	Number Of Shares Shorted	3.23 M
	Price To Book	2.18 X
	EBITDA	(74.81 M)
	Net Income	(71.17 M)
	Cash And Equivalents	151.48 M
	Cash Per Share	3.77 X
	Total Debt	46.59 M
	Debt To Equity	0.02 %
	Current Ratio	14.54 X
	Book Value Per Share	1.29 X
	Cash Flow From Operations	(70.67 M)
	Short Ratio	14.61 X
	Earnings Per Share	(1.55) X
	Price To Earnings To Growth	(0.06) X
	Target Price	18.75
	Number Of Employees	59
	Beta	1.54
	Market Capitalization	180.51 M
	Total Asset	200.85 M
	Retained Earnings	(285.93 M)
	Working Capital	181.56 M
	Net Asset	200.85 M

About Inozyme Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Inozyme Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inozyme Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inozyme Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Inozyme Stock Analysis

When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC